Clinical Trial Detail

NCT ID NCT02787369
Title ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

CLL/SLL

Therapies

Idelalisib + Ricolinostat

Ibrutinib + Ricolinostat

Age Groups: adult

No variant requirements are available.